1-6 of 6
Frederic Triebel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma

Martin Forster, Irene Brana, Antonio L. Pousa, Bernard Doger, Patricia Roxburgh, Pawan Bajaj, Julio Peguero, Matthew Krebs, Enric Carcereny, Grisma Patel, Christian Mueller, Chrystelle Brignone, Frederic Triebel
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3726–3734.
https://doi.org/10.1158/1078-0432.CCR-24-0473
Published: 03 September 2024
View article titled, Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma
Open the PDF for Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial

Hans Wildiers, Anne Armstrong, Eveline Cuypere, Florence Dalenc, Luc Dirix, Steve Chan, Frederik Marme, Carolina P. Schröder, Jens Huober, Francois P. Duhoux, Peter Vuylsteke, Agnes Jager, Etienne Brain, Sherko Kuemmel, Zsuzsanna Pápai, Catharina Willemien Menke-van der Houven van Oordt, Luca Perjesi, Christian Mueller, Chrystelle Brignone, Frederic Triebel
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (3): 532–541.
https://doi.org/10.1158/1078-0432.CCR-23-1173
Published: 01 February 2024
View article titled, Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR<sup>+</sup> Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial
Open the PDF for Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR<sup>+</sup> Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial in another window
Includes: Supplementary data
Journal Articles

Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial

Amandine Legat, Hélène Maby-El Hajjami, Petra Baumgaertner, Laurène Cagnon, Samia Abed Maillard, Christine Geldhof, Emanuela M. Iancu, Luc Lebon, Philippe Guillaume, Danijel Dojcinovic, Olivier Michielin, Emanuela Romano, Grégoire Berthod, Donata Rimoldi, Frédéric Triebel, Immanuel Luescher, Nathalie Rufer, Daniel E. Speiser
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1330–1340.
https://doi.org/10.1158/1078-0432.CCR-15-1212
Published: 14 March 2016
View article titled, Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial
Open the PDF for Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer

Nicolas A. Giraldo, Etienne Becht, Franck Pagès, Georgios Skliris, Virginie Verkarre, Yann Vano, Arnaud Mejean, Nicolas Saint-Aubert, Laetitia Lacroix, Ivo Natario, Audrey Lupo, Marco Alifano, Diane Damotte, Aurelie Cazes, Frederic Triebel, Gordon J. Freeman, Marie-Caroline Dieu-Nosjean, Stephane Oudard, Wolf H. Fridman, Catherine Sautès-Fridman
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (13): 3031–3040.
https://doi.org/10.1158/1078-0432.CCR-14-2926
Published: 30 June 2015
View article titled, Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
Open the PDF for Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma

Chrystelle Brignone, Bernard Escudier, Caroline Grygar, Manon Marcu, Frédéric Triebel
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6225–6231.
https://doi.org/10.1158/1078-0432.CCR-09-0068
Published: 30 September 2009
View article titled, A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
Open the PDF for A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Lymphocyte Activation Gene-3 Fusion Protein Increases the Potency of a Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy

Betty Li, Melinda VanRoey, Frederic Triebel, Karin Jooss
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (11): 3545–3554.
https://doi.org/10.1158/1078-0432.CCR-07-5200
Published: 02 June 2008
View article titled, Lymphocyte Activation Gene-3 Fusion Protein Increases the Potency of a Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy
Open the PDF for Lymphocyte Activation Gene-3 Fusion Protein Increases the Potency of a Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy in another window